

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	10/525,115
Filing Date	August 31, 2005
First Named Inventor	Martin Hendrix
Art Unit	1624
Examiner Name	Jeffrey H. Murray
Attorney Docket Number	01-2112

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	A1	3 189 955	05-05-1961	Schmidt et al.	
	A2	3 211 731	10-12-1955	Schmidt et al.	
	A3	7 515 555	11-10-2009	Hendrix et al.	
	A4	6 458 795	10-01-2001	Haning et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	B1	WO-2006 125548	11-30-2006	BAYER HEALTHCARE AG		C8
	B2	CH-398 626	03-15-1966	CIBA GEIGY		A2
	B3	WO-2004 096811	11-11-2004	PFIZER PROD INC		A3
	B4	WO-2004 099210	11-18-2004	BAYER HEALTHCARE AG		
	B5	WO-2004 099211	11-18-2004	BAYER HEALTHCARE AG		C9
	B6	WO-2003 041725	05-22-2003	BAYER AG		A3
	B7	WO-2002 09713	02-07-2002	BAYER AG		A3
	B8	WO-1996 28429	09-19-1996	SANOFI WINTHROP, INC.		
	B9	WO-2003 037432	05-08-2003	PFIZER PRODUCTS, INC.		
	B10	JP-2002 523507	07-30-2002			A4

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ² Applicant's unique citation designation number (optional). ³ See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9109 and select option 2.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	10/525,115
Filing Date	August 31, 2005
First Named Inventor	Martin Hendrix
Art Unit	1624
Examiner Name	Jeffrey H. Murray
Attorney Docket Number	01-2112

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	VAN DER STAAY, J. ET AL., "The Novel selective PDE9 inhibitor BAY 73-6591 improves learning and memory in rodents," <i>Neuropharmacology</i> , 2008, Vol. 55, pp. 908-918	
	C2	FRANCIS, P. T., "Glutamatergic systems in Alzheimer's Disease," <i>International Journal of the Geriatric Psychiatry</i> , 2003, Vol. 18, pp. S15-S21	
	C3	FRANCIS, P. T. ET AL., "Cortical Pyramidal Neurons Loss May Cause Glutamatergic Hypoactivity and Cognitive Impairment in Alzheimer's Disease: Investigative and Therapeutic Perspectives," <i>Journal of Neurochemistry</i> , 1993	
	C4	PUZZO, D. ET AL., "Amyloid-Beta Peptide Inhibits Activation of the Nitric Oxide/cGMP/cAMP-Responsive Element-Binding Protein Pathway during Hippocampal Synaptic Plasticity" <i>Neurobiology of Disease</i> , July 20, 2005, Vol. 25, No. 29, pp. 6887-6897	
	C5	REYMANN, K. G. ET AL., "The late maintenance of hippocampal LTP: Requirements, phases, 'synaptic tagging', 'late associativity' and the implications," <i>Neuropharmacology</i> , 2007, Vol. 52, pp. 24-40	
	C6	WANG, H. ET AL., "Insight into Binding of Phosphodiesterase-9A Selective Inhibitors by Crystal Structures and Mutagenesis," <i>Journal of Medicinal Chemistry</i> , October 12, 2009	
	C7	DENINNO, M. P. ET AL., "The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents," <i>Bioorganic & Medicinal Chemistry Letters</i> , 2009, Vol. 19, pp. 2537-2541	
	C8	HENDRIX ET AL., "Use of Pyrazolopyrimidine Against Cardiovascular Disease," Publication Date: November 30, 2006, Data Supplied from the espacenet database Worldwide; English Abstract of WO 2006125548	
	C9	HENDRIX ET AL., "6-cyclylmethyl- and 6-alkylmethyl-Substituted Pyrazolopyrimidines," Publication Date: November 18, 2004, Data Supplied from the espacenet database Worldwide; English Abstract of WO 2004092211	
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.